Markets:

Overview

News

Currencies

International

Treasuries

Alto Neuroscience, Inc. Common Stock (NY:ANRO)

16.77 -1.04 (-5.81%)

Streaming Delayed Price Updated: 11:24 AM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alto Neuroscience, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Alto Neuroscience Is Down Nearly 35% This Year, But Retail Traders Keep Flocking To Micro-Cap Stock ↗

March 03, 2025

While ALTO-100's Phase 2 results failed to meet expectations, the company has emphasized the potential of ALTO-300, another MDD treatment currently in Phase 2b trials.

Via Stocktwits

Alto Neuroscience to Participate in Upcoming Investor Conferences

February 25, 2025

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker

February 19, 2025

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial

February 12, 2025

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Investors With Losses Are Invited To Contact The Schall Law Firm

December 16, 2024

Via ACCESSWIRE

This Addus HomeCare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

December 16, 2024

Via Benzinga

The Schall Law Firm Encourages Stockholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud

December 15, 2024

Via ACCESSWIRE

Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Affected Investors Are Invited To Contact The Schall Law Firm

December 14, 2024

Via ACCESSWIRE

The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Possible Securities Fraud

December 13, 2024

Via ACCESSWIRE

Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Investors With Losses Are Invited To Contact The Schall Law Firm

December 12, 2024

Via ACCESSWIRE

Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology

December 11, 2024

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights

November 12, 2024

From Alto Neuroscience, Inc.

Via Business Wire

ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm

November 04, 2024

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Alto Neuroscience to Participate in Upcoming Investor Conferences

November 04, 2024

From Alto Neuroscience, Inc.

Via Business Wire

ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm

October 27, 2024

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Nasdaq Down 2%; US Crude Stocks Increase ↗

October 23, 2024

Via Benzinga

Neuropsychiatry-Focused Alto Neuroscience's Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About Platform ↗

October 23, 2024

Alto Neuroscience's ALTO-100 Phase 2b study for major depressive disorder failed to meet its primary endpoint, but the company plans further data analysis and studies.

Via Benzinga

Gold Moves Lower; AT&T Earnings Top Views ↗

October 23, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 23, 2024

Via Benzinga

Dow Tumbles Over 250 Points; Boeing Posts Q3 Loss ↗

October 23, 2024

Via Benzinga

Topics Stocks

Enphase Energy Posts Downbeat Results, Joins McDonald's, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

October 23, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

October 23, 2024

Via Benzinga

Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket ↗

October 23, 2024

Via Benzinga

ANRO Investors Have Opportunity to Join Alto Neuroscience, Inc. Fraud Investigation with the Schall Law Firm

October 22, 2024

From The Schall Law Firm

Via Business Wire

Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder

October 22, 2024

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Announces Peer-Reviewed Publication in the Journal of Clinical Psychiatry Demonstrating Baseline Cognitive Performance is Not a Moderator of Response to Standard-of-Care Antidepressants

September 04, 2024

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience to Participate in Upcoming Investor Conferences

September 03, 2024

From Alto Neuroscience, Inc.

Via Business Wire

ANRO Stock Earnings: Alto Neuroscience Beats EPS for Q2 2024 ↗

August 13, 2024

ANRO stock results show that Alto Neuroscience beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Alto Neuroscience Reports Second Quarter 2024 Financial Results and Recent Business Highlights

August 13, 2024

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Receives Funding Award from Wellcome Trust to Accelerate Development of ALTO-100 in Bipolar Depression Leveraging Precision Psychiatry Approach

July 25, 2024

From Alto Neuroscience, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.